An observational study in Smoking, Cigarette, sponsored by Rose Research Center, LLC. Completed at 2 sites in United States. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-01-13.
Sponsored by Rose Research Center, LLC · Observational
The main objective of this study is to determine the accuracy and precision of the iCOquit Smokerlyzer as compared with the gold standard of COHb levels measured in venous plasma samples, as well as assessing its agreement with the Vitalograph BreathCO monitor. Validating the precision and accuracy of the iCOquit Smokerlyzer could establish an additional, less expensive, reliable method for determining smoking status in tobacco research. Additionally, the portability of the device would allow for remote biochemical verification of smoking status, thus enlarging the number of participants that can be included in intervention studies.
Rose Research Center, LLC is the lead sponsor of 13 studies on the registry; none are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 3 (38%) have results posted.
Counted across the registry records on this site, refreshed daily.
Combustible cigarette smokers from Raleigh, NC and Charlotte, NC and surrounding areas.
Exclusion Criteria:
Use of any of these products in the past 30 days:
Participant enrollment numbers met.
-
eCO Monitor Accuracy compared to COHb
Determine the accuracy and precision of the iCOquit Smokerlyzer as compared with the gold standard of COHb levels measured in venous plasma samples.
Time frame: Baseline
eCO Monitor's agreement with the Vitalograph BreathCO monitor
Comparing the CO values from the eCO Monitor and the Vitalograph BreathCO monitor.
Time frame: Baseline
eRESEARCH APP VALIDATION
Validate a new mobile app called eResearch through specific functionality testing by study participants.
Time frame: Daily for 5 days
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rose Research Center, LLC